At least 31 biotechs and pharmas are slated to report earnings this week. Anika Therapeutics Inc. (NASDAQ:ANIK), Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) and Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) are all expected to post quarterly EPS growth of more than 20%. Anika markets hyaluronic acid-based products for osteoarthritis and other indications and is expected to report a 15% increase in revenues to $17 million. Questcor markets H.P. Acthar Gel repository corticotropin injection for autoimmune and inflammatory disorders and is expected to report a 42% increase in revenues to $199.7 million. Specialty pharma Valeant is expected to report revenues of $1.7 billion, up from $884 million, driven by contributions from acquired businesses. Biogen Idec Inc. (NASDAQ:BIIB) and Gilead Sciences Inc. (NASDAQ:GILD) are anticipated to announce strong top line growth